From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).

There are no approved pharmacotherapies for stimulant use disorders. Lots of medications have been studied and the results have been mixed. Here we provide you with the latest data, and some treatment recommendations.

Dr. de la Cruz gives advice for working with patients with addiction to prescription and illicit stimulants. She provides concrete strategies for diagnosis, harm reduction, evidence-based treatments, and contingency management in this challenging patient population.

Predictions that overdose mortality would worsen during the COVID-19 pandemic have unfortunately proven accurate. Recent data outlined in an alert by the CDC show that rates of overdose deaths from opioids and stimulants have accelerated at an alarming rate.

Does ADHD bring creative strengths? Can stimulants dampen creative thought? New research suggests they can, but the effect varies by patient.

When we choose medications, we typically think that we are paying attention to risks and benefits. But what happens when we just look through the lens of side effects? An entirely different picture emerges of what medications might be the better picks. You will be surprised and intrigued by this review of a very helpful study that will probably change your prescribing patterns.